SALT LAKE CITY, May 3 /PRNewswire-FirstCall/ -- Aquagen International, Inc. (Other OTC: AQGI.PK), today released the results from another clinical study completed at the University of Cairo.
"This study was commissioned by the medical school at the University of Cairo in March 2001 and like other studies completed at the Cairo Medial School, we were just recently given authorization to release the study and its findings to the public," said Joanne Clinger, Aquagen's CEO. "The name of this study is 'The Effect of a Liquid Oxygen Supplement (Aquagen(R)) on the Arterial Partial Pressure of Oxygen in Normal and Hypoxic Guinea Pigs' and it was conducted with the 60 guinea pigs," said Clinger.
"The published results of this study revealed that Aquagen(R), given orally, resulted in significant elevation of arterial blood - oxygen levels in both normal and hypoxic guinea pigs. The results further stated that not only did Aquagen(R) increase blood - oxygen levels, but it also may help to improve oxygen transportation in the body," said Clinger. "The study concluded by suggesting that several other conditions may benefit from Aquagen(R) use, such as: 1) pre-term infants with bronchopulmonary displasia; 2) anti-tumor therapy; and 3) humans with cystic fibrosis, congestive heart failure, bronchial asthma and chronic hypoxia and that athletes may also benefit from Aquagen(R) use," said Wayne Reichmann, President of Aquagen's wholly owned subsidiary, Aquagen Manufacturing. "As with the other University of Cairo study, this study has not been reviewed by the FDA. These are independent studies that show the efficacy of our Aquagen(R) product for various disorders, conducted by independent third parties," said Clinger. "Anyone interested can review the summary of this study, as well as other studies, on our website at http://www.aquagen.com/," said Reichmann.
"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995
Statements in this press release relating to plans, strategies, economic performance and trends, projections of results of specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue," or similar terms or the negative of these terms. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. The company has no obligation to update these forward-looking statements."
Aquagen International, Inc.